Osseon Therapeutics, Inc. Signs Distribution Agreement with DePuy Spine, Inc.
10/6/2010 10:34:49 AM
SANTA ROSA, Calif., Oct. 6 /PRNewswire/ -- Osseon® Therapeutics, Inc. announced today that the company has entered into an agreement with DePuy Spine, Inc. for the distribution of its Osseoflex® steerable spine augmentation needle throughout the U.S. Osseon's technology provides a minimally invasive treatment for vertebral compression fractures (VCFs that may result from osteoporosis and benign or malignant lesions.).
Osseoflex is a steerable, physician controlled VCF needle that provides navigation within the vertebral body allowing pinpoint treatment for spinal disease. Osseoflex enables direct access to the entire vertebral body by way of a unipedicular approach for percutaneous vertebral augmentation. The procedure augments vertebral compression fractures that may result from osteoporosis and benign or malignant lesions by steering and channeling the Osseoflex needle through the bone, thereby creating voids for bone cement deposits within the vertebral body. After the bone cavities are created, the CONFIDENCE SPINAL CEMENT SYSTEM is injected through the Osseoflex needle directly to the pathological sites within the vertebrae.
The agreement gives DePuy distribution rights in the U.S. to sell Osseoflex alongside its CONFIDENCE SPINAL CEMENT SYSTEM directly through their sales network. Osseon will continue to maintain a direct sales force in strategic territories in the U.S. and Europe.
"This is a major development for Osseon," said John Stalcup, Ph.D., Osseon's President and Chief Executive Officer. "Since the launch of Osseoflex in January, 2009, we have achieved excellent treatment results and sales growth while performing over 1,000 cases and treating over 1,400 VCFs in the U.S. and Europe. This agreement allows us to achieve even greater market penetration through DePuy's extensive market presence and their highly regarded medical device sales organization. We look forward to working with DePuy to significantly expand the availability of Osseoflex treatments for patients in the U.S."
About Osseon Therapeutics, Inc.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. For more information, visit our web site at www.osseon.com.
Osseon® is a registered trademark of Osseon Therapeutics, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
SOURCE Osseon Therapeutics, Inc.